ArticleCardiovascular diabetology2026
The cholesterol, high-density lipoprotein, and glucose index and its derived indices predict diabetic kidney disease development and progression: evidence from two nationwide cohorts and a biopsy-proven clinical cohort.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Associations of cumulative exposure and dynamic trajectories of the cholesterol-HDL-glucose index and its obesity-related derivatives with cardiovascular disease: a nationwide prospective cohort study.Cardiovascular diabetology · 2026Article
- Waist-to-height ratio modifies the association between cardiometabolic indices and incident carotid plaque: evidence from a Chinese cohort.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe Cholesterol, High-Density Lipoprotein, and Glucose (CHG) index is a recently proposed composite metric, but its utility in predicting the development and progression of diabetic kidney disease (DKD) remains insufficiently explored. This study aimed to evaluate the predictive value of the CHG index and its anthropometric-adjusted derivatives for DKD development and progression, comparing their performance with traditional surrogate markers of insulin resistance.
methodsWe analyzed 10-year longitudinal data from the China Health and Retirement Longitudinal Study (CHARLS, 2011–2020), including 984 diabetic patients without baseline renal injury. Incident DKD risk was evaluated using Cox proportional hazards models and Kaplan–Meier analysis, while restricted cubic splines (RCS) assessed non-linear dose–response relationships. External validation utilized the cross-sectional National Health and Nutrition Examination Survey (NHANES 1999–2018). Furthermore, disease progression (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2) was evaluated in an independent clinical cohort of 217 patients with biopsy-proven DKD. Discriminative ability was evaluated via Receiver Operating Characteristic (ROC) analyses. Subgroup and interaction analyses evaluated prognostic consistency across patient profiles.
resultsIn CHARLS, elevated CHG-BMI independently predicted incident DKD in fully adjusted models (Quartile 3 HR = 2.19, P = 0.020), showing significant integrated discrimination improvement (IDI, P = 0.030) over traditional markers. Subgroup analyses revealed higher risk estimates for CHG-BMI in non-overweight and normolipidemic individuals (P for interaction < 0.05). NHANES analysis replicated these associations, identifying significant J-shaped trajectories for CHG and CHG-BMI. In the biopsy-proven cohort, CHG and CHG-BMI were independently associated with reduced eGFR (P < 0.05), unlike traditional markers. They yielded adjusted AUCs of 0.733 and 0.730 for predicting DKD progression. E-value analysis for unmeasured confounding was 4.81 for CHG-BMI (Q3). Significant interactions emerged between CHG-BMI and Renal Pathology Society (RPS) grades, with significant associations in classes IIa and IIb.
conclusionThe CHG index and CHG-BMI independently predict DKD development and progression, outperforming traditional insulin resistance markers. Both indices aid clinical risk stratification, with CHG-BMI specifically identifying elevated risks in early pathological stages and among individuals without overt metabolic comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.